Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Decreases By 45.5%

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 31,800 shares, a drop of 45.5% from the October 31st total of 58,400 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily volume of 44,200 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

Several equities analysts have recently commented on TLSI shares. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Canaccord Genuity Group reduced their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Roth Mkm began coverage on TriSalus Life Sciences in a report on Monday, November 11th. They set a “buy” rating and a $11.00 price target for the company. Finally, Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $12.08.

Insider Transactions at TriSalus Life Sciences

In other news, CEO Mary T. Szela acquired 7,520 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average price of $5.20 per share, with a total value of $39,104.00. Following the completion of the transaction, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This trade represents a 2.03 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have acquired 19,560 shares of company stock valued at $95,190. 32.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently added to or reduced their stakes in the business. Highbridge Capital Management LLC acquired a new stake in TriSalus Life Sciences in the second quarter valued at $1,184,000. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences in the second quarter valued at about $240,000. Duquesne Family Office LLC raised its position in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of TriSalus Life Sciences in the third quarter worth approximately $92,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Trading Up 7.3 %

TLSI traded up $0.31 on Friday, reaching $4.56. The stock had a trading volume of 12,179 shares, compared to its average volume of 39,311. The firm has a 50-day moving average of $4.23 and a 200-day moving average of $5.43. The company has a market capitalization of $139.05 million, a price-to-earnings ratio of -1.83 and a beta of 0.49. TriSalus Life Sciences has a fifty-two week low of $3.61 and a fifty-two week high of $10.42.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.